|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Axillary lymph node management in breast cancer with positive sentinel lymph node biopsy显示文摘The surgical treatment of localized breast cancer has become progressively less aggressive over the years.The management of the axillary lymph nodes has been modified by the introduction of sentinel lymph node biopsy. Axillary dissection can be avoided in patients with sentinel lymph node negative biopsies. Based on randomized trials data, it has been proposed that no lymph node dissection should be carried out even in certain patients with sentinel lymph node positive biopsies. This commentary discusses the basis of such recommendations and cautions against a general omission of lymph node dissection in breast cancer patients with positive sentinel lymph node biopsies. Instead, an individualized approach based on axillary tumor burden and biology of the cancer should be considered. | Ioannis A Voutsadakis Silvana Spadafora | 2015 | World Journal of Clinical Oncology2015，6，1： | 7 |
| 2 | Thrombocytosis as a prognostic marker in gastrointestinal cancers显示文摘Thrombocytosis is an adverse prognostic factor in many types of cancer. These include breast cancer, ovarian and other gynecologic cancers, renal cell carcinoma and lung cancers. In gastrointestinal cancers of various locations and histologic types, thrombocytosis has been reported in general to be associated with adverse clinical outcomes. Platelet count measurement is well standardized and available in every clinical laboratory, making its use as a prognostic marker practical. This paper will discuss the data on the prognostic value of thrombocytosis in gastrointestinal cancers as well as pathogenic aspects of the association that strengthen the case for its use in clinical prognostication. | Ioannis A Voutsadakis | 2014 | World Journal of Gastrointestinal Oncology2014，6，2： | 6 |
| 3 | Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy:Rational and current status显示文摘Chemotherapy given in a metronomic manner can be administered with less adverse effects which are common with conventional schedules such as myelotoxicity and gastrointestinal toxicity and thus may be appropriate for older patients and patients with decreased performance status. Efficacy has been observed in several settings. An opportunity to improve the efficacy of metronomic schedules without significantly increasing toxicity presents with the addition of anti-angiogenic targeted treatments. These combinations rational stems from the understanding of the importance of angiogenesis in the mechanism of action of metronomic chemotherapy which may be augmented by specific targeting of the vascular endothelial growth factor(VEGF) pathway by antibodies or small tyrosine kinase inhibitors. Combinations of metronomic chemotherapy schedules with VEGF pathway targeting drugs will be discussed in this paper. | Antonia Digklia Ioannis A Voutsadakis | 2014 | World Journal of Experimental Medicine2014，4，4： | 4 |
| 4 | Peroxisome proliferator activated receptor-γ and the ubiquitin-proteasome system in colorectal cancer显示文摘Peroxisome proliferator activated receptor-γ (PPARγ), a transcription factor of the nuclear receptor superfamily plays a significant role in colorectal cancer pathogenesis. In most experimental systems PPARγ activation has tumor suppressing effects in the colon. PPARγ is regulated at multiple levels by the ubiquitin-proteasome system (UPS). At a first level, UPS regulates PPARγ transcription. This regulation involves both PPARγ transcription specific factors and the general transcription machinery. At a second level UPS regulates PPARγ and its co-factors themselves, as PPARγ and many co-factors are proteasome substrates. At a third level of regulation, transduction pathways working in parallel but also having interrelations with PPARγ are regulated by the UPS, creating a network of regulation in the colorectal carcinogenesisrelated pathways that are under UPS control. Activation of PPARγ transcription by direct pharmacologic activators and by stabilization of its molecule by proteasome inhibitors could be strategies to be exploited in colorectal cancer treatment. | Ioannis A Voutsadakis | 2010 | World Journal of Gastrointestinal Oncology2010，2，5： | 3 |
| 5 | Molecular predictors of gemcitabine response in pancreatic cancer显示文摘Gemcitabine is one of the most used anti-neoplastic drugs with documented activity in almost all major localizations of cancer.In pancreatic cancer treatment,gemcitabine occupies a prominent place as a first line chemotherapy,partly because of the paucity of other efficacious chemotherapy options.In fact,only a minority of pancreatic cancer patients display a response or even stability of disease with the drug.There are currently no clinically applicable means of predicting which patient will derive a clinical benefit from gemcitabine although several proposed markers have been studied. These markers are proteins involved in drug up-take,activation and catabolism or proteins that define the ability of the cell to undergo apoptosis in response to the drug.Several of these markers are reviewed in this paper.We also briefly discuss the possible role of stem cells in drug resistance to gemcitabine. | Ioannis A Voutsadakis | 2011 | World Journal of Gastrointestinal Oncology2011，3，11： | 3 |
| 6 | 为变形食道的有鳞的房间癌症的指向的治疗显示文摘 Squamous cell carcinoma, one of the two major subtypes of esophageal carcinomas, constitutes the great majority of tumors in the upper and middle third of the organ. Declining in incidence in western countries, it continues to be a significant public health problem in the far east. Targeted treatments are novel therapies introduced in the clinical therapeutic armamentarium of oncology in the last 10-15 years. They represent a rational way of treating various cancers based on their molecular lesions. Although no such agent has been approved so far for the treatment of esophageal squamous cell carcinomas (ESCC), several are in clinical trials and several others have displayed pre-clinical activity that would justify the efforts and risks of pursuing their clinical development in this disease. This paper discusses some of these targeted agents in more advanced development in metastatic ESCC, as well as some promising drugs with pre-clinical or initial clinical data in the disease. | Antonia Digklia Ioannis A Voutsadakis | 2013 | World Journal of Gastrointestinal Oncology2013，5，5： | 2 |
| 7 | Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies显示文摘BACKGROUND BRIP1 is a helicase that partners with BRCA1 in the homologous recombination(HR) step in the repair of DNA inter-strand cross-link lesions. It is a rare cause of hereditary ovarian cancer in patients with no mutations of BRCA1 or BRCA2. The role of the protein in other cancers such as gastrointestinal(GI) carcinomas is less well characterized but given its role in DNA repair it could be a candidate tumor suppressor similarly to the two BRCA proteins.AIM To analyze the role of helicase BRIP1(FANCJ) in GI cancers pathogenesis.METHODS Publicly available data from genomic studies of esophageal, gastric, pancreatic,cholangiocarcinomas and colorectal cancers were interrogated to unveil the role of BRIP1 in these carcinomas and to discover associations of lesions in BRIP1 with other more common molecular defects in these cancers.RESULTS Molecular lesions in BRIP1 were rare(3.6% of all samples) in GI cancers and consisted almost exclusively of mutations and amplifications. Among mutations,40% were possibly pathogenic according to the Onco KB database. A majority of BRIP1 mutated GI cancers were hyper-mutated due to concomitant mutations in mismatch repair or polymerase ε and δ1 genes. No associations were discovered between amplifications of BRIP1 and any mutated genes. In gastroesophageal cancers BRIP1 amplification commonly co-occurs with ERBB2 amplification.CONCLUSION Overall BRIP1 molecular defects do not seem to play a major role in GI cancers whereas mutations frequently occur in hypermutated carcinomas and co-occur with other HR genes mutations. Despite their rarity, BRIP1 defects may present an opportunity for therapeutic interventions similar to other HR defects. | Ioannis A Voutsadakis | 2020 | World Journal of Gastroenterology2020，26，11： | 2 |
| 8 | Apoptosis and the pathogenesis of lymphoma显示文摘 | Voutsadakis IA | | 0，，02： | 2 |
| 9 | Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer显示文摘 | Stravodimou A Voutsadakis IA | 2013 | Int J Breast Cancer2013，2013，28： | 1 |
| 10 | Malignant female adnexal tumor of probable wolffian origin relapsing after pregnancy显示文摘 | David Atallah Roman Rouzier Ioannis Voutsadakis Claude Sader-Ghorra Joseph Azoury Sophie Camatte Philippe Morice Pierre Duvillard | 2004 | Gynecologic Oncology2004，，2： | 1 |
| 11 | Apoptosis and the pathogenesis of lymphoma 显示文摘 | Voutsadakis IA | 2000 | Acta 0ncol2000，39，： | 1 |
| 12 | A 'turnon' coumarin-based fluorescent sensor with high selectivity for mercury ions in aqueous media显示文摘 | Voutsadaki S Tsikalas G K Klontzas E | | 0，，： | 1 |
| 13 | Bone and brain metastases from ampullary adenocarcinoma显示文摘Ampullary carcinoma is the second most common cancer of the peri-ampullary area after pancreatic carcinoma and metastasizes mostly intra-abdominally and to the liver.Extra-abdominal metastases are less frequent.In this report we describe the case of a patient with resected adenocarcinoma of the ampulla of Vater who developed skeletal metastases in the lower extremity and brain metastases.We briefly discuss aspects of this comparatively rare gastrointestinal malignancy. | Ioannis A Voutsadakis Stergios Doumas Konstantinos Tsapakidis Maria Papagianni Christos N Papandreou | 2009 | World Journal of Gastroenterology2009，15，21： | 1 |
| 14 | Apoptosis and the pathogenesis of lymphoma显示文摘 | Voutsadakis IA | 2000 | Acta Oncol2000，39，： | 1 |
| 15 | NK cells in allogeneic bone marrow transplantation显示文摘 | Voutsadakis IA | 2003 | Cancer Immunol Immunother2003，52，9： | 1 |
| 16 | Apoptosis and the pathogenesis of lymphoma 显示文摘 | Voutsadakis IA | 2000 | Acta Oncol2000，39，2： | 1 |
| 17 | Malignant female adnexal tumor of probable wolffian origin relapsing after pregnancy显示文摘 | Atallah D Rouzier R Voutsadakis I | | 0，，02： | 1 |
| 18 | Pre-treatment platelet counts as a prognostic and predictive factor in stage Ⅱ and Ⅲ rectal adenocarcinoma显示文摘AIM To investigate if pre-treatment platelet counts could provide prognostic information in patients with rectal adenocarcinoma that received neo-adjuvant treatment. METHODS Platelet number on diagnosis of stage II and III rectal cancer was evaluated in 51 patients receiving neoadjuvant treatment and for whom there were complete follow-up data on progression and survival, as well as pathologic outcome at the time of surgery. Pathologic responses on the surgical specimen of patients with lower platelet counts(150-300 × 10~9/L) were compared with these of patients with higher platelet counts(> 300 × 10~9/L) by the χ~2 test. Overall and progression free survival Kaplan-Meier curves of the two groups were constructed and compared with the Log-Rank test.RESULTS A significant difference was present between the two groups in regards to pathologic response with patients with lower platelet counts being more likely to exhibit a good or complete response to neo-adjuvant treatment than patients with higher platelet counts(P = 0.015). Among other factors evaluated, there was also a significant difference between the carcinoembryonic antigen(CEA) at presentation of patients that exhibited a good or complete response and those that had no response or a minimal to moderate response. Patients with a good or complete response were more likely to present with a CEA of less than 5 μg/L(P = 0.00066). There was no significant difference in overall and progression free survival between the two platelet count groups(Log-Rank tests P = 0.42 and P = 0.35, respectively).CONCLUSION In this retrospective analysis of stage II and III rectal cancer patients, platelet counts at the time of diagnosis had prognostic value for neo-adjuvant treatment pathologic response. Pre-treatment CEA also held prognostic value in regards to treatment effect. | Morgan Steele Ioannis A Voutsadakis | 2017 | World Journal of Gastrointestinal Oncology2017，9，1： | 1 |
| 19 | Interferon-alpha and the pathogenesis of myeloproliferative disorders显示文摘 | Voutsadakis IA | 2000 | MedOncol2000，17，4： | 1 |
| 20 | Apoptosis and the pathogenesis of lympho- ma 显示文摘 | Voutsadakis IA | 2000 | Acta Oncol2000，39，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员